Skip to main content
. 2018 Mar 3;32(2):373–379. doi: 10.21873/invivo.11248

Table I. Overall survival according to various clinical factors related to pericardiocentesis and pericardial cisplatin therapy.

graphic file with name in_vivo-32-375-i0001.jpg

WBC: White blood cells; NTproBNP: N-terminal pro-B type natriuretic peptide; HR: hazard ratio; CI: confidence interval

HHS Vulnerability Disclosure